Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 199

1.

Transitions to and from long-term care facilities and length of completed stay: Reuse of population-based survey data.

Broad JB, Lumley T, Ashton T, Davis PB, Boyd M, Connolly MJ.

Australas J Ageing. 2017 Jun;36(2):E1-E7. doi: 10.1111/ajag.12378. Epub 2017 Mar 20.

PMID:
28319325
2.

Epidemiology of Cystic Fibrosis.

Spoonhower KA, Davis PB.

Clin Chest Med. 2016 Mar;37(1):1-8. doi: 10.1016/j.ccm.2015.10.002. Review.

PMID:
26857763
3.
4.

Likelihood of residential aged care use in later life: a simple approach to estimation with international comparison.

Broad JB, Ashton T, Gott M, McLeod H, Davis PB, Connolly MJ.

Aust N Z J Public Health. 2015 Aug;39(4):374-9. doi: 10.1111/1753-6405.12374. Epub 2015 Jun 11.

PMID:
26095070
5.

Research in academic medical centers: two threats to sustainable support.

Levine AS, Alpern RJ, Andrews NC, Antman K, Balser JR, Berg JM, Davis PB, Fitz JG, Golden RN, Goldman L, Jameson JL, Lee VS, Polonsky KS, Rappley MD, Reece EA, Rothman PB, Schwinn DA, Shapiro LJ, Spiegel AM.

Sci Transl Med. 2015 May 27;7(289):289fs22. doi: 10.1126/scitranslmed.aac5200.

PMID:
26019216
6.

Another Beginning for Cystic Fibrosis Therapy.

Davis PB.

N Engl J Med. 2015 Jul 16;373(3):274-6. doi: 10.1056/NEJMe1504059. Epub 2015 May 17. No abstract available.

PMID:
25981385
7.

Non-covalent ligand conjugation to biotinylated DNA nanoparticles using TAT peptide genetically fused to monovalent streptavidin.

Sun W, Fletcher D, van Heeckeren RC, Davis PB.

J Drug Target. 2012 Sep;20(8):678-90. doi: 10.3109/1061186X.2012.712128.

8.

Ivacaftor.

Davis PB, Yasothan U, Kirkpatrick P.

Nat Rev Drug Discov. 2012 Apr 30;11(5):349-50. doi: 10.1038/nrd3723. No abstract available.

PMID:
22543461
9.

An unparalleled engine for discovery and clinical introduction: the clinical and translational science awards and gene therapy.

Davis PB.

Hum Gene Ther. 2012 Mar;23(3):251-3. doi: 10.1089/hum.2012.2504. No abstract available.

10.

Therapy for cystic fibrosis--the end of the beginning?

Davis PB.

N Engl J Med. 2011 Nov 3;365(18):1734-5. doi: 10.1056/NEJMe1110323. No abstract available.

PMID:
22047565
11.

Genetic variation and clinical heterogeneity in cystic fibrosis.

Drumm ML, Ziady AG, Davis PB.

Annu Rev Pathol. 2012;7:267-82. doi: 10.1146/annurev-pathol-011811-120900. Epub 2011 Oct 17. Review.

12.

Methods for evaluating inflammation in cystic fibrosis.

Ziady AG, Davis PB.

Methods Mol Biol. 2011;742:51-76. doi: 10.1007/978-1-61779-120-8_4.

PMID:
21547726
13.

Nucleolin-mediated cellular trafficking of DNA nanoparticle is lipid raft and microtubule dependent and can be modulated by glucocorticoid.

Chen X, Shank S, Davis PB, Ziady AG.

Mol Ther. 2011 Jan;19(1):93-102. doi: 10.1038/mt.2010.214. Epub 2010 Oct 19.

14.

Preparation and analysis of PEGylated poly-L-lysine DNA nanoparticles for gene delivery.

Davis PB, Kowalczyk TH.

Cold Spring Harb Protoc. 2010 May;2010(5):pdb.prot5419. doi: 10.1101/pdb.prot5419.

PMID:
20439407
15.

Reducible DNA nanoparticles enhance in vitro gene transfer via an extracellular mechanism.

Sun W, Davis PB.

J Control Release. 2010 Aug 17;146(1):118-27. doi: 10.1016/j.jconrel.2010.04.031. Epub 2010 May 12.

16.

Driving quality improvement in local public health practice.

Davis PB, Solomon J, Gorenflo G.

J Public Health Manag Pract. 2010 Jan-Feb;16(1):67-71. doi: 10.1097/PHH.0b013e3181c2c7f7.

PMID:
20009647
17.

The triterpenoid CDDO limits inflammation in preclinical models of cystic fibrosis lung disease.

Nichols DP, Ziady AG, Shank SL, Eastman JF, Davis PB.

Am J Physiol Lung Cell Mol Physiol. 2009 Nov;297(5):L828-36. doi: 10.1152/ajplung.00171.2009. Epub 2009 Aug 21.

18.

Plasma Renin test-guided drug treatment algorithm for correcting patients with treated but uncontrolled hypertension: a randomized controlled trial.

Egan BM, Basile JN, Rehman SU, Davis PB, Grob CH 3rd, Riehle JF, Walters CA, Lackland DT, Merali C, Sealey JE, Laragh JH.

Am J Hypertens. 2009 Jul;22(7):792-801. doi: 10.1038/ajh.2009.63. Epub 2009 Apr 16.

PMID:
19373213
19.

S163 is critical for FXYD5 modulation of wound healing in airway epithelial cells.

Miller TJ, Davis PB.

Wound Repair Regen. 2008 Nov-Dec;16(6):791-9. doi: 10.1111/j.1524-475X.2008.00432.x.

20.

Treatment of tinnitus with a customized, dynamic acoustic neural stimulus: clinical outcomes in general private practice.

Hanley PJ, Davis PB, Paki B, Quinn SA, Bellekom SR.

Ann Otol Rhinol Laryngol. 2008 Nov;117(11):791-9.

PMID:
19102123
21.

Treatment of tinnitus with a customized, dynamic acoustic neural stimulus: underlying principles and clinical efficacy.

Hanley PJ, Davis PB.

Trends Amplif. 2008 Sep;12(3):210-22. doi: 10.1177/1084713808319942. Epub 2008 Jul 9.

22.

Treatment of tinnitus with a customized acoustic neural stimulus: a controlled clinical study.

Davis PB, Wilde RA, Steed LG, Hanley PJ.

Ear Nose Throat J. 2008 Jun;87(6):330-9.

PMID:
18561116
23.

Peroxisome proliferator-activated receptor-gamma in cystic fibrosis lung epithelium.

Perez A, van Heeckeren AM, Nichols D, Gupta S, Eastman JF, Davis PB.

Am J Physiol Lung Cell Mol Physiol. 2008 Aug;295(2):L303-13. doi: 10.1152/ajplung.90276.2008. Epub 2008 Jun 13.

24.

FXYD5 modulates Na+ absorption and is increased in cystic fibrosis airway epithelia.

Miller TJ, Davis PB.

Am J Physiol Lung Cell Mol Physiol. 2008 Apr;294(4):L654-64. doi: 10.1152/ajplung.00430.2007. Epub 2008 Feb 8.

25.

Cell surface nucleolin serves as receptor for DNA nanoparticles composed of pegylated polylysine and DNA.

Chen X, Kube DM, Cooper MJ, Davis PB.

Mol Ther. 2008 Feb;16(2):333-42. Epub 2007 Dec 4.

26.

Clinical use of Ibuprofen is associated with slower FEV1 decline in children with cystic fibrosis.

Konstan MW, Schluchter MD, Xue W, Davis PB.

Am J Respir Crit Care Med. 2007 Dec 1;176(11):1084-9. Epub 2007 Sep 13.

27.

Pacing the marathon: rate of decline of pulmonary function in cystic fibrosis.

Davis PB.

J Pediatr. 2007 Aug;151(2):111-3. No abstract available.

PMID:
17643757
28.

Neuromonics Tinnitus Treatment: third clinical trial.

Davis PB, Paki B, Hanley PJ.

Ear Hear. 2007 Apr;28(2):242-59.

PMID:
17496674
29.

Cystic fibrosis: a review of epidemiology and pathobiology.

Strausbaugh SD, Davis PB.

Clin Chest Med. 2007 Jun;28(2):279-88. Review.

PMID:
17467547
30.

Vectors for airway gene delivery.

Davis PB, Cooper MJ.

AAPS J. 2007 Jan 19;9(1):E11-7. Review.

31.

Claiming behaviour in a no-fault system of medical injury: a descriptive analysis of claimants and non-claimants.

Bismark MM, Brennan TA, Davis PB, Studdert DM.

Med J Aust. 2006 Aug 21;185(4):203-7.

PMID:
16922665
32.

CFTR inhibition mimics the cystic fibrosis inflammatory profile.

Perez A, Issler AC, Cotton CU, Kelley TJ, Verkman AS, Davis PB.

Am J Physiol Lung Cell Mol Physiol. 2007 Feb;292(2):L383-95. Epub 2006 Aug 18.

33.

Current prospects for gene therapy of cystic fibrosis.

Ziady AG, Davis PB.

Curr Opin Pharmacol. 2006 Oct;6(5):515-21. Epub 2006 Aug 4. Review.

PMID:
16890018
34.
35.

Response to acute lung infection with mucoid Pseudomonas aeruginosa in cystic fibrosis mice.

van Heeckeren AM, Schluchter MD, Xue W, Davis PB.

Am J Respir Crit Care Med. 2006 Feb 1;173(3):288-96. Epub 2005 Nov 4.

36.

Cystic fibrosis since 1938.

Davis PB.

Am J Respir Crit Care Med. 2006 Mar 1;173(5):475-82. Epub 2005 Aug 26. Review.

PMID:
16126935
37.
38.

Antibodies to the polymeric immunoglobulin receptor with different binding and trafficking patterns.

Gupta S, Heacock M, Perez A, Davis PB.

Am J Respir Cell Mol Biol. 2005 Oct;33(4):363-70. Epub 2005 Jun 30.

39.

Compacted DNA nanoparticles administered to the nasal mucosa of cystic fibrosis subjects are safe and demonstrate partial to complete cystic fibrosis transmembrane regulator reconstitution.

Konstan MW, Davis PB, Wagener JS, Hilliard KA, Stern RC, Milgram LJ, Kowalczyk TH, Hyatt SL, Fink TL, Gedeon CR, Oette SM, Payne JM, Muhammad O, Ziady AG, Moen RC, Cooper MJ.

Hum Gene Ther. 2004 Dec;15(12):1255-69.

PMID:
15684701
40.
41.

Some like it hot: curcumin and CFTR.

Davis PB, Drumm ML.

Trends Mol Med. 2004 Oct;10(10):473-5. Review.

PMID:
15464445
42.

Relation of sweat chloride concentration to severity of lung disease in cystic fibrosis.

Davis PB, Schluchter MD, Konstan MW.

Pediatr Pulmonol. 2004 Sep;38(3):204-9.

PMID:
15274098
43.

Defining strategies to extend duration of gene expression from targeted compacted DNA vectors.

Ziady AG, Kim J, Colla J, Davis PB.

Gene Ther. 2004 Sep;11(18):1378-90.

PMID:
15269710
44.
45.

Role of Cftr genotype in the response to chronic Pseudomonas aeruginosa lung infection in mice.

van Heeckeren AM, Schluchter MD, Drumm ML, Davis PB.

Am J Physiol Lung Cell Mol Physiol. 2004 Nov;287(5):L944-52. Epub 2004 Jul 9.

46.

Nutritional effects on host response to lung infections with mucoid Pseudomonas aeruginosa in mice.

van Heeckeren AM, Schluchter M, Xue L, Alvarez J, Freedman S, St George J, Davis PB.

Infect Immun. 2004 Mar;72(3):1479-86.

47.

Minimal toxicity of stabilized compacted DNA nanoparticles in the murine lung.

Ziady AG, Gedeon CR, Muhammad O, Stillwell V, Oette SM, Fink TL, Quan W, Kowalczyk TH, Hyatt SL, Payne J, Peischl A, Seng JE, Moen RC, Cooper MJ, Davis PB.

Mol Ther. 2003 Dec;8(6):948-56.

48.

Transfection of airway epithelium by stable PEGylated poly-L-lysine DNA nanoparticles in vivo.

Ziady AG, Gedeon CR, Miller T, Quan W, Payne JM, Hyatt SL, Fink TL, Muhammad O, Oette S, Kowalczyk T, Pasumarthy MK, Moen RC, Cooper MJ, Davis PB.

Mol Ther. 2003 Dec;8(6):936-47.

49.

Delivery of CFTR by adenoviral vector to cystic fibrosis mouse lung in a model of chronic Pseudomonas aeruginosa lung infection.

Van Heeckeren AM, Scaria A, Schluchter MD, Ferkol TW, Wadsworth S, Davis PB.

Am J Physiol Lung Cell Mol Physiol. 2004 Apr;286(4):L717-26. Epub 2003 Sep 26.

50.

Supplemental Content

Loading ...
Support Center